偉星新材(002372.SZ):偉星集團、章卡鵬及張三雲合計持股比例被動稀釋至45.67%
格隆匯 12 月 21日丨偉星新材(002372.SZ)公佈,公司第三期股權激勵計劃以限制性股票的激勵形式向143名激勵對象定向發行1900萬股普通股股票,該部分股份於2020年12月21日完成授予登記並上市,公司總股本由15.73億增加至15.92億股,因此導致偉星集團、章卡鵬、張三雲持股比例被動稀釋,由原持股比例38.35%、5.25%、2.62%分別變為37.90%、5.18%、2.59%。偉星集團與章卡鵬、張三云為一致行動人,綜上,其持有公司股份比例減少變動超過1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.